Top Markets
#1 ADO Protocol ADO Protocol +329.06%
#2 GoPlus Security GoPlus Security +53.78%
#3 Starpower Starpower +49.28%
#4 The Black Bull The Black Bull +36.13%
#5 Verus Coin Verus Coin +33.62%
#6 Nockchain Nockchain +33.50%
#7 Tutorial Tutorial +33.08%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +31.73%
#9 GAIB AID GAIB AID +24.67%
#10 Fake World Assets Fake World Assets +21.93%
Coin of the day
ADO Protocol ADO Protocol
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
NuCana plc NuCana plc

NuCana plc

NCNA
Rang in Aktien #32670
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Aktienkurs
$1.51
Marktkapitalisierung
$9.14M
Veränderung (1 Tag)
-5.35%
Veränderung (1 Jahr)
-59.65%
Land
GB
Handel NuCana plc (NCNA)

Kategorie

Healthcare
Anzahl der ausstehenden Aktien von NuCana plc (NCNA)
Anzahl der ausstehenden Aktien zum August 2026: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von NuCana plc beträgt die aktuelle Anzahl der ausstehenden Aktien 0. Am Ende von August 2026 hatte das Unternehmen 0 ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von NuCana plc (NCNA) von 2026 bis 2026
Ausstehende Aktien am Ende jedes Jahres
Jahr Ausstehende Aktien ändert
Nicht genügend Daten für die angegebenen Daten.
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
Unternehmen Ausstehende Aktien Unterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -
BE